- Home
- LFST vs HCM Comparison
LFST vs HCM Comparison
Compare LFST & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFST
- HCM
- Stock Information
- Founded
- LFST 2015
- HCM 2000
- Country
- LFST United States
- HCM Hong Kong
- Employees
- LFST N/A
- HCM N/A
- Industry
- LFST Medical/Nursing Services
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- LFST Health Care
- HCM Health Care
- Exchange
- LFST Nasdaq
- HCM Nasdaq
- Market Cap
- LFST 2.3B
- HCM 2.5B
- IPO Year
- LFST 2021
- HCM N/A
- Fundamental
- Price
- LFST $5.94
- HCM $13.89
- Analyst Decision
- LFST Strong Buy
- HCM Hold
- Analyst Count
- LFST 5
- HCM 1
- Target Price
- LFST $8.50
- HCM $19.00
- AVG Volume (30 Days)
- LFST 2.0M
- HCM 62.8K
- Earning Date
- LFST 05-07-2025
- HCM 03-19-2025
- Dividend Yield
- LFST N/A
- HCM N/A
- EPS Growth
- LFST N/A
- HCM N/A
- EPS
- LFST N/A
- HCM 0.04
- Revenue
- LFST $1,283,503,000.00
- HCM $630,201,000.00
- Revenue This Year
- LFST $15.35
- HCM $14.86
- Revenue Next Year
- LFST $13.72
- HCM $19.54
- P/E Ratio
- LFST N/A
- HCM $63.20
- Revenue Growth
- LFST 16.31
- HCM N/A
- 52 Week Low
- LFST $4.64
- HCM $11.51
- 52 Week High
- LFST $8.61
- HCM $21.50
- Technical
- Relative Strength Index (RSI)
- LFST 46.63
- HCM 50.07
- Support Level
- LFST $5.47
- HCM $13.13
- Resistance Level
- LFST $6.18
- HCM $13.66
- Average True Range (ATR)
- LFST 0.20
- HCM 0.36
- MACD
- LFST 0.05
- HCM 0.05
- Stochastic Oscillator
- LFST 66.20
- HCM 81.25
About LFST LifeStance Health Group Inc.
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.